Article Text
Statistics from Altmetric.com
In probably the first allusion to publication bias, the British natural philosopher Robert Boyle said in 1661: “Many excellent notions or experiments are, by sober and modest men, suppressed.”1 Since then a large body of evidence has emerged to substantiate the existence of publication bias—that is, a tendency on the part of investigators or editors to fail to publish study results on the basis of the direction or strength of the study findings. Studies with negative or uncertain results are less likely to be published; even if they are, they take longer to appear than studies with positive results. Some investigators classify publication bias into three types: non-publication, abbreviated publication, and time-lag bias.2 In clinical medicine, publication bias usually comes to light as non-publication or delayed publication of trials that do not favour a new therapeutic intervention. This bias pervades all disciplines of science and medicine, including of course neurology. Although all areas in neurology are probably subject to this bias, the evidence for its …
Read the full text or download the PDF:
Other content recommended for you
- SOCRATES 2 (synopsis of Cochrane reviews applicable to emergency services)
- Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis
- Recent progress in drug treatment for acute stroke
- Potential for quality improvement of acute stroke management in a district general hospital
- Guidelines for evaluation and management of cerebral collateral circulation in ischaemic stroke 2017
- European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischemic Stroke
- Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke: multicentre, open label, randomised, controlled trial
- Benefits and safety of transdermal glyceryl trinitrate in acute stroke: a systematic review and meta-analysis of randomised trials (protocol)
- Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA
- Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis